all report title image
  • Published On : Jan 2022
  • Code : CMI4886
  • Industry : Pharmaceutical
  • Pages : 165
  • Formats :
Ingographics Image

Canine atopic dermatitis is an inflammatory, chronic skin disease associated with allergies. This is the second most common allergic skin disease in dogs. The major cause of atopic dermatitis in dogs is harmful allergen such as animal dander, airborne pollens, mold spores, and house dust. This disease in dogs is often hereditary and exposure to any harmful allergen can trigger the onset of canine atopic dermatitis. Its symptoms include excessive itching and scratching, hair loss, greasy or flaky skin with a foul odor, and excessive scratching on the paws and areas such as the groin and armpits.

Market Dynamics

The global canine atopic dermatitis treatment drugs market is expected to witness high growth over the forecast period, owing to increasing pet ownership.

However, the high cost associated with cyclosporine, glucocorticoids, immunotherapy, and oral histamines treatment therapies is a major factor restraining the global canine atopic dermatitis treatment drugs market growth. For instance, the cost of canine atopic dermatitis treatment ranges from US$ 600 to US$ 1,100 depending on the type and severity of atopic dermatitis. An additional cost of diagnostic tests, sedation for injection, and others may include more than US$ 200 to US$ 300.

Key features of the study:

  • This report provides an in-depth analysis of the global canine atopic dermatitis treatment drugs market, market size (US$ Mn), and compound annual growth rate (CAGR %) during the forecast period: 2021 – 2028, considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players operating in this market
  • It profiles key players in the global canine atopic dermatitis treatment drugs market based on the following parameters–company overview, financial performance, product portfolio, geographical presence, key developments, and strategies.
  • Key players covered as a part of this study include Zoetis Inc., Elanco Animal Health Incorporated, Virbac, Kindred Biosciences, Inc., Nippon Zenyaku Kogyo Co., Ltd. (ZENOAQ), Bioiberica S.A.U, Dechra Pharmaceuticals PLC, and Toray Industries, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global canine atopic dermatitis treatment drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for global canine atopic dermatitis treatment drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Canine Atopic Dermatitis Treatment Drugs Market, By Drug Class:
    • Janus Kinase Inhibitors
    • Immunosuppressant
    • Monoclonal Antibody
    • Antibiotics
    • Others
  • Global Canine Atopic Dermatitis Treatment Drugs Market, By Route of  Administration:
    • Injection
    • Oral
    • Topical
  • Global Canine Atopic Dermatitis Treatment Drugs Market, By Distribution Channel:
    • Hospital and Clinics
    • Retail Pharmacies
    • Online Pharmacies
  • Global Canine Atopic Dermatitis Treatment Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Zoetis Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Elanco Animal Health Incorporated
    • Virbac
    • Kindred Biosciences, Inc.
    • Nippon Zenyaku Kogyo Co., Ltd. (ZENOAQ)
    • Bioiberica S.A.U
    • Dechra Pharmaceuticals PLC
    • Toray Industries, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Detailed Segmentation:

  • Global Canine Atopic Dermatitis Treatment Drugs Market, By Drug Class:
    • Janus Kinase Inhibitors
    • Immunosuppressant
    • Monoclonal Antibody
    • Antibiotics
    • Others
  • Global Canine Atopic Dermatitis Treatment Drugs Market, By Route of  Administration:
    • Injection
    • Oral
    • Topical
  • Global Canine Atopic Dermatitis Treatment Drugs Market, By Distribution Channel:
    • Hospital and Clinics
    • Retail Pharmacies
    • Online Pharmacies
  • Global Canine Atopic Dermatitis Treatment Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Class:
        • Janus kinase Inhibitors
        • Immunosuppressant
        • Monoclonal Antibody
        • Antibiotics
        • Others
      • By Route of Administration:
        • Injection
        • Oral
        • Topical
      • By Distribution Channel
        • Hospital and Clinics
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Class:
        • Janus kinase Inhibitors
        • Immunosuppressant
        • Monoclonal Antibody
        • Antibiotics
        • Others
      • By Route of Administration:
        • Injection
        • Oral
        • Topical
      • By Distribution Channel
        • Hospital and Clinics
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Class:
        • Janus kinase Inhibitors
        • Immunosuppressant
        • Monoclonal Antibody
        • Antibiotics
        • Others
      • By Route of Administration:
        • Injection
        • Oral
        • Topical
      • By Distribution Channel
        • Hospital and Clinics
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Class:
        • Janus kinase Inhibitors
        • Immunosuppressant
        • Monoclonal Antibody
        • Antibiotics
        • Others
      • By Route of Administration:
        • Injection
        • Oral
        • Topical
      • By Distribution Channel
        • Hospital and Clinics
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Class:
        • Janus kinase Inhibitors
        • Immunosuppressant
        • Monoclonal Antibody
        • Antibiotics
        • Others
      • By Route of Administration:
        • Injection
        • Oral
        • Topical
      • By Distribution Channel
        • Hospital and Clinics
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Class:
        • Janus kinase Inhibitors
        • Immunosuppressant
        • Monoclonal Antibody
        • Antibiotics
        • Others
      • By Route of Administration:
        • Injection
        • Oral
        • Topical
      • By Distribution Channel
        • Hospital and Clinics
        • Retail Pharmacies
        • Online Pharmacies

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo